Summary

The Europe nucleic acid therapeutics, sport food additives and skin care market is expected to reach USD 6.07 billion by 2032 from USD 3.56 billion in 2024, growing with a substantial CAGR of 6.95% in the forecast period of 2025 to 2032.

Market Segmentation:
Europe Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market, By Product (Nucleic Acid Therapeutic, Nucleic Acid Skin Care Products, and Nucleic Acid Sports Food Additives), Source (Natural Nucleic Acids and Synthetic Nucleic Acids), End User (Individual Consumers/ Home Healthcare, and Professional/Facility Use), Distribution Channel (Direct Tender, Retail Sales, and Others), Countries (Germany, France, U.K., Italy, Russia, Spain, Belgium, Netherlands, Denmark, Switzerland, Norway, Sweden, Finland, Turkey, Poland, and Rest of Europe) - Industry Trends and Forecast to 2032


Overview for Europe Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market Dynamics:

Driver
• Growing demand for functional foods, nutraceuticals, and bioactive skincare ingredients
Restraint
• High costs associated with production and research & development
Opportunity
• Breakthroughs in RNA and DNA-based therapies, food additives, and skincare innovations
Market Players:

The key players operating in the Europe nucleic acid therapeutics, sport food additives and skin care market are:
• Pfizer Inc.
• Novartis AG
• AstraZeneca
• Sarepta Therapeutics, Inc.
• Alnylam Pharmaceuticals, Inc.
• Zhejiang Haichang Biopharmaceutical Technology Co., Ltd.
• Moderna, Inc.
• Biogen
• Ionis Pharmaceuticals, Inc.
• Spark Therapeutics, Inc.
• DNA Skin Institute
• Remy Laure
• Juliette Armand
• PostQuam
• Kalichem s.r.l.
• MoonGlow
• Bio Jouvance Paris Consumer

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 110
1.1 OBJECTIVES OF THE STUDY 110
1.2 MARKET DEFINITION 110
1.3 OVERVIEW 110
1.4 LIMITATIONS 113
1.5 MARKETS COVERED 113
2 MARKET SEGMENTATION 125
2.1 MARKETS COVERED 125
2.2 GEOGRAPHICAL SCOPE 126
2.3 YEARS CONSIDERED FOR THE STUDY 127
2.4 CURRENCY AND PRICING 127
2.5 DBMR TRIPOD DATA VALIDATION MODEL 128
2.6 MULTIVARIATE MODELING 131
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 132
2.8 DBMR MARKET POSITION GRID 133
2.9 DBMR VENDOR SHARE ANALYSIS 135
2.10 MARKET END USER COVERAGE GRID 137
2.11 SECONDARY SOURCES 139
2.12 ASSUMPTIONS 139
3 EXECUTIVE SUMMARY 140
4 PREMIUM INSIGHTS 145
4.1 PESTAL ANALYSIS 149
4.2 PORTER’S FIVE FORCES 150
4.2.1 THREAT OF NEW ENTRANTS 150
4.2.2 BARGAINING POWER OF BUYERS 151
4.2.3 BARGAINING POWER OF SUPPLIERS 151
4.2.4 THREAT OF SUBSTITUTES 151
4.2.5 COMPETITIVE RIVALRY 152
4.3 IMPORT EXPORT SCENARIO 153
4.4 PRICING ANALYSIS 154
4.5 PRODUCTION CAPACITY FOR TOP MANUFACTURERS 155
4.6 BRAND OUTLOOK 156
4.6.1 BRAND COMPARATIVE ANALYSIS OF EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET 156
4.6.2 PRODUCT VS BRAND OVERVIEW 157
4.6.2.1 PRODUCT OVERVIEW 157
4.6.2.2 BRAND OVERVIEW 158
4.7 CONSUMER BUYING BEHAVIOUR FOR THE EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND EUROPE NUCLEIC ACID SKIN CARE MARKET 159
4.7.1 AWARENESS AND EDUCATION 159
4.7.2 HEALTH AND PERFORMANCE-ORIENTED BUYERS 159
4.7.3 PREFERENCE FOR NATURAL AND SCIENTIFIC FORMULATIONS 159
4.7.4 PRICE SENSITIVITY AND WILLINGNESS TO PAY FOR QUALITY 160
4.7.5 ROLE OF BRAND TRUST AND REVIEWS 160
4.7.6 DIGITAL-FIRST SHOPPING EXPERIENCE 160
4.7.7 REGULATORY AND SAFETY CONCERNS 161
4.7.8 SUSTAINABILITY AND ETHICAL CONSIDERATIONS 161
4.8 FACTORS AFFECTING BUYING DECISION FOR EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND EUROPE NUCLEIC ACID SKIN CARE MARKET 162
4.8.1 SCIENTIFIC VALIDATION AND EFFICACY 162
4.8.2 PRICE AND PERCEIVED VALUE 162
4.8.3 BRAND REPUTATION AND TRUST 162
4.8.4 PERSONAL HEALTH AND SKIN CONCERNS 163
4.8.5 DIGITAL INFLUENCE AND E-COMMERCE ACCESSIBILITY 163
4.8.6 REGULATORY APPROVALS AND SAFETY ASSURANCE 163
4.8.7 ETHICAL AND SUSTAINABILITY CONSIDERATIONS 164
4.8.8 AVAILABILITY AND CONVENIENCE 164
4.9 IMPACT OF ECONOMIC SLOWDOWN ON EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND EUROPE NUCLEIC ACID SKIN CARE MARKET 165
4.9.1 IMPACT ON PRICE 165
4.9.2 IMPACT ON SUPPLY CHAIN 165
4.9.3 IMPACT ON SHIPMENT 165
4.9.4 IMPACT ON DEMAND 165
4.9.5 IMPACT ON STRATEGIC DECISIONS 166
4.10 PRODUCT ADOPTION SCENARIO FOR EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND EUROPE NUCLEIC ACID SKIN CARE MARKET 167
4.10.1 AWARENESS AND MARKET PENETRATION 167
4.10.2 CONSUMER SEGMENTATION AND ADOPTION TRENDS 167
4.10.3 INFLUENCE OF SCIENTIFIC RESEARCH AND REGULATORY APPROVALS 168
4.10.4 PRICING, ACCESSIBILITY, AND DISTRIBUTION CHANNELS 168
4.11 RAW MATERIAL SOURCING ANALYSIS 170
4.11.1 SOURCES OF NUCLEIC ACIDS FOR FOOD ADDITIVES AND SKINCARE 170
4.11.2 SUPPLY CHAIN CHALLENGES IN RAW MATERIAL PROCUREMENT 170
4.11.3 QUALITY CONTROL AND REGULATORY COMPLIANCE 170
4.11.4 COST IMPLICATIONS OF RAW MATERIAL SOURCING 170
4.11.5 SUSTAINABILITY AND ETHICAL SOURCING 170
4.12 SUPPLY CHAIN ANALYSIS FOR EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND EUROPE NUCLEIC ACID SKIN CARE MARKETS 172
4.13 OVERVIEW 172
4.13.1 LOGISTIC COST SCENARIO 172
4.13.2 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 172
4.14 PATENT ANALYSIS 173
4.15 PIPELINE 176
4.16 MERGERS & ACQUISITIONS 179
4.17 INDUSTRY INSIGHTS 180
5 PIPELINE ANALYSIS: 188
6 EPIDEMIOLOGY 194
6.1 INCIDENCE BY GENDER 194
6.2 TREATMENT RATES 194
6.3 MORTALITY RATES 194
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODELS 195
6.5 PATIENT TREATMENT SUCCESS RATES 195
7 REGULATORY COVERAGE 197
8 MARKET OVERVIEW 198
8.1 DRIVERS 200
8.1.1 GROWING DEMAND FOR FUNCTIONAL FOODS, NUTRACEUTICALS, AND BIOACTIVE SKINCARE INGREDIENTS 200
8.1.2 RISING INFLUENCE OF PERSONALIZED MEDICINE AND CUSTOMIZED SKINCARE SOLUTIONS 201
8.1.3 FAVORABLE REGULATORY POLICIES AND RISING R&D INVESTMENTS IN GENE-BASED THERAPIES 202
8.1.4 INCREASING PREVALENCE OF CHRONIC DISEASES AND AN AGING EUROPE POPULATION 203
8.2 RESTRAINTS 205
8.2.1 INCREASING TREATMENT COSTS DUE TO HIGH PRODUCTION EXPENSES IN GENE-BASED THERAPIES 205
8.2.2 POTENTIAL RISKS AND SIDE EFFECTS OF GENE-BASED TREATMENTS 206
8.3 OPPORTUNITIES 207
8.3.1 BREAKTHROUGHS IN RNA AND DNA-BASED THERAPIES, FOOD ADDITIVES, AND SKINCARE INNOVATIONS 207
8.3.2 EXPANSION THROUGH STRATEGIC PARTNERSHIPS AND COLLABORATIONS 208
8.3.3 TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY SYSTEMS 209
8.4 CHALLENGES 211
8.4.1 LOW PUBLIC AWARENESS AND SLOW ADOPTION RATES 211
8.4.2 INTELLECTUAL PROPERTY COMPLEXITIES AND PATENT-RELATED HURDLES 212
9 EUROPE NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY PRODUCT 213
9.1 OVERVIEW 214
9.2 NUCLEIC ACID THERAPEUTICS 215
9.2.1 BY CATEGORY 216
9.2.1.1 ANTISENSE 216
9.2.1.1.1 BY MOLECULES 216
9.2.1.1.1.1 NUSINERSEN 217
9.2.1.1.1.2 ETEPLIRSEN 217
9.2.1.1.1.3 GOLODIRSEN 217
9.2.1.1.1.4 INOTERSEN 217
9.2.1.1.1.5 VOLANESORSEN 217
9.2.1.1.1.6 OTHERS 217
9.2.1.1.2 BY DRUGS 217
9.2.1.1.2.1 SPINRAZA 217
9.2.1.1.2.2 EXONDYS 51 217
9.2.1.1.2.3 TEGSEDI 217
9.2.1.1.2.4 OTHERS 217
9.2.2 RNA INTERFERENCE 218
9.2.2.1 BY MOLECULES 218
9.2.2.1.1 VUTRISIRAN 218
9.2.2.1.2 GIVOSIRAN 218
9.2.2.1.3 PATISIRAN 218
9.2.2.1.4 LUMASIRAN 218
9.2.2.2 BY DRUGS 219
9.2.2.2.1 AMVUTRA 219
9.2.2.2.2 GIVLAARI 219
9.2.2.2.3 ONPATTRO 219
9.2.2.2.4 OXLUMO 219
9.2.2.3 BY TYPE 220
9.2.2.3.1 DOUBLE-STRANDED RNA VIRUSES (DSRNA) 220
9.2.2.3.2 SMALL INTERFERING RNA (SIRNA) 220
9.2.2.3.3 MICRORNAS (MIRNA) 220
9.2.3 CPG OLIGONUCLEOTIDES 221
9.2.3.1 BY TYPE 221
9.2.3.1.1 CPG ADJUVANTS IN VACCINES 221
9.2.3.1.2 TYPE B CPG OLIGONUCLEOTIDES 221
9.2.4 APTAMERS 221
9.2.5 OTHERS 221
9.2.6 BY STRUCTURE 222
9.2.6.1 SINGLE-STRANDED RNA 222
9.2.6.2 DOUBLE-STRANDED DNA 222
9.2.6.3 SINGLE-STRANDED DNA 222
9.2.6.4 SINGLE-STRANDED RNA/DNA 222
9.2.7 BY DRUG TYPE 223
9.2.7.1 MARKETED/ APPROVED DRUGS 223
9.2.7.1.1 SMALL NUCLEIC ACID DRUGS 223
9.2.7.1.2 MRNA VACCINES 223
9.2.7.1.3 OTHERS 223
9.2.7.2 PIPELINE DRUGS 223
9.2.8 BY APPLICATION 224
9.2.8.1 GENETIC DISORDERS 224
9.2.8.2 NEUROLOGICAL DISORDERS 224
9.2.8.3 INFECTIOUS DISEASES 224
9.2.8.4 AUTOIMMUNE DISEASES 224
9.2.8.5 OTHERS 224
9.2.9 BY ROUTE OF ADMINISTRATION 225
9.2.9.1 INTRATHECAL 225
9.2.9.2 SUBCUTANEOUS 225
9.2.9.3 INTRAVENOUS 225
9.2.9.4 OTHERS 225
9.3 NUCLEIC ACID SKIN CARE PRODUCTS 226
9.3.1 DNA-BASED SKIN CARE 227
9.3.1.1 DNA REPAIR SERUMS 227
9.3.1.1.1 ANTI-AGING DNA SERUMS 227
9.3.1.1.2 HYDRATING DNA SERUMS 227
9.3.1.1.3 DNA-BASED COLLAGEN-BOOSTING SERUMS 227
9.3.2 DNA-INFUSED MOISTURIZERS 228
9.3.2.1.1 DAY CREAMS 228
9.3.2.1.2 NIGHT CREAMS 228
9.3.2.1.3 DEEP HYDRATION CREAMS 228
9.3.2.1.4 OTHERS 228
9.3.2.2 DNA-BASED SUNSCREENS 228
9.3.2.2.1 BROAD-SPECTRUM UV PROTECTION 228
9.3.2.2.2 ANTI-PHOTOAGING DNA SUNSCREENS 228
9.3.2.3 DNA-BASED FACE MASKS 229
9.3.2.3.1 SHEET MASKS 229
9.3.2.3.2 CLAY MASKS 229
9.3.2.3.3 GEL MASKS 229
9.3.2.3.4 OTHERS 229
9.3.2.4 DNA-INFUSED EYE CREAMS 230
9.3.2.4.1 ANTI-DARK CIRCLE CREAMS 230
9.3.2.4.2 FINE LINE & WRINKLE REDUCTION CREAMS 230
9.3.2.4.3 PUFFINESS REDUCTION CREAMS 230
9.3.2.4.4 OTHERS 230
9.4 RNA-BASED SKIN CARE 231
9.4.1 RNA-INFUSED CREAMS 231
9.4.1.1 ANTI-AGING RNA CREAMS 231
9.4.1.2 BARRIER REPAIR CREAMS 231
9.4.1.3 INTENSIVE MOISTURE CREAMS 231
9.4.1.4 OTHERS 231
9.4.2 RNA-BASED ANTI-AGING TREATMENTS 232
9.4.2.1 WRINKLE REDUCTION FORMULATIONS 232
9.4.2.2 SKIN REJUVENATION TREATMENTS 232
9.4.2.3 OTHERS 232
9.4.3 GENE THERAPY-INFUSED SKIN CARE PRODUCTS 233
9.4.3.1 PERSONALIZED SKINCARE WITH DNA/RNA MODIFICATIONS 233
9.4.3.2 EPIGENETIC SKIN CARE TREATMENTS 233
9.4.3.3 OTHERS 233
9.4.4 BY SKIN TYPE 234
9.4.4.1 DRY SKIN 234
9.4.4.2 NORMAL SKIN 234
9.4.4.3 OILY SKIN 234
9.4.4.4 COMBINATION SKIN 234
9.4.4.5 SENSITIVE SKIN 234
9.4.4.6 OTHERS 234
9.4.5 BY PACKAGING 235
9.4.5.1 BOTTLES 235
9.4.5.1.1 SQUEEZE BOTTLES 235
9.4.5.1.2 PUMP BOTTLES 235
9.4.5.1.3 SPRAY BOTTLES 235
9.4.5.1.4 OTHERS 235
9.4.5.2 TUBES 236
9.4.5.2.1 TWIST CAPS 236
9.4.5.2.2 FLIP-TOP CAPS 236
9.4.5.2.3 AIRLESS SQUEEZE TUBES 236
9.4.5.2.4 OTHERS 236
9.4.5.3 DROPPER BOTTLES 237
9.4.5.3.1 PIPETTE DROPPERS 237
9.4.5.3.2 PUSH-BUTTON DROPPERS 237
9.4.5.4 JARS 237
9.4.5.4.1 SCREW-TOP LIDS 237
9.4.5.4.2 FLIP-TOP LIDS 237
9.4.5.4.3 SPATULA-INCLUDED JARS 237
9.4.5.4.4 OTHERS 237
9.4.5.5 AMPOULES 238
9.4.5.5.1 SINGLE-USE AMPOULES 238
9.4.5.5.2 MULTI-DOSE AMPOULES 238
9.4.5.6 SACHETS AND POUCHES 239
9.4.5.6.1 TEAR-OFF SACHETS 239
9.4.5.6.2 RESEALABLE POUCHES 239
9.4.5.7 OTHERS 239
9.4.6 BY PACKAGING SIZE 240
9.4.6.1 MEDIUM-SIZED PACKAGING (31 ML – 75 ML) 240
9.4.6.2 SMALL-SIZED PACKAGING (1 ML – 30 ML) 240
9.4.6.3 LARGE-SIZED PACKAGING (76 ML – 200 ML) 240
9.4.6.4 EXTRA-LARGE PACKAGING (ABOVE 200 ML) 240
9.4.7 BY PRICE RANGE 241
9.4.7.1 MASS 241
9.4.7.2 PREMIUM 241
9.4.7.3 LUXURY 241
9.4.8 BY APPLICATION 242
9.4.8.1 MOISTURIZATION & HYDRATION 242
9.4.8.1.1 DEEP HYDRATION WITH NUCLEIC ACIDS 243
9.4.8.1.1.1 DNA-BASED WATER-LOCK CREAMS 243
9.4.8.1.1.2 RNA-POWERED HYDRATION BOOSTERS 243
9.4.8.1.2 LONG-LASTING HYDRATION SERUMS 243
9.4.8.1.2.1 24-HOUR HYDRATION RNA SERUMS 243
9.4.8.1.2.2 DNA-POWERED MOISTURE-LOCKING TREATMENTS 243
9.4.8.1.3 SKIN BARRIER STRENGTHENING 244
9.4.8.1.3.1 NUCLEIC ACID-INFUSED CERAMIDE CREAMS 244
9.4.8.1.3.2 EPIGENETIC SKIN RESILIENCE ENHANCERS 244
9.4.8.2 SKIN REGENERATION & REPAIR 245
9.4.8.2.1 POST-SURGERY & INTENSIVE HEALING TREATMENTS 245
9.4.8.2.2 DNA-BASED WOUND HEALING CREAMS 245
9.4.8.2.3 RNA-INFUSED SCAR-REPAIR SERUMS 245
9.4.8.2.4 SKIN BARRIER RECOVERY FORMULATIONS 245
9.4.8.2.5 CELLULAR RENEWAL TREATMENTS 246
9.4.8.2.5.1 DNA-STIMULATING SKIN RENEWAL SERUMS 246
9.4.8.2.5.2 RNA-BASED ENZYMATIC SKIN REPAIR MASKS 246
9.4.8.2.6 DNA DAMAGE REPAIR 246
9.4.8.2.6.1 UV-INDUCED DNA DAMAGE REVERSAL CREAMS 246
9.4.8.2.6.2 EPIGENETIC REPAIR SERUMS 246
9.4.8.2.6.3 OTHERS 246
9.4.8.3 UV PROTECTION & SUN DAMAGE REPAIR 247
9.4.8.3.1 DNA-BASED SUNSCREENS 247
9.4.8.3.1.1 BROAD-SPECTRUM UVA/UVB PROTECTION 247
9.4.8.3.1.2 PHOTOAGING DEFENSE FORMULAS 247
9.4.8.3.2 AFTER-SUN DNA REPAIR TREATMENTS 248
9.4.8.3.2.1 DNA-INFUSED POST-SUN EXPOSURE MASKS 248
9.4.8.3.2.2 RNA-BASED SUNBURN RECOVERY GELS 248
9.4.8.3.3 BLUE LIGHT & POLLUTION PROTECTION 248
9.4.8.3.3.1 DNA-POWERED DIGITAL DEFENSE CREAMS 248
9.4.8.3.3.2 RNA-BASED ENVIRONMENTAL SHIELD SERUMS 248
9.4.8.4 ACNE & SCAR TREATMENT 249
9.4.8.4.1 DNA-BASED ACNE CONTROL SERUMS 249
9.4.8.4.1.1 ANTI-BACTERIAL NUCLEIC ACID SERUMS 249
9.4.8.4.1.2 SEBUM-REGULATING RNA TREATMENTS 249
9.4.8.4.2 RNA-POWERED SCAR FADING CREAMS 250
9.4.8.4.2.1 POST-ACNE MARK CORRECTORS 250
9.4.8.4.2.2 EPIGENETIC TISSUE REGENERATION SERUMS 250
9.4.8.4.3 HORMONAL ACNE TREATMENTS 250
9.4.8.4.3.1 DNA-BASED HORMONAL BALANCING SKINCARE 250
9.4.8.4.3.2 RNA-INFUSED ANTI-INFLAMMATORY GELS 250
9.4.8.4.4 OIL-CONTROL & PORE REDUCTION 251
9.4.8.4.4.1 DNA-POWERED OIL-BALANCING CREAMS 251
9.4.8.4.4.2 RNA-BASED PORE-TIGHTENING TONERS 251
9.4.8.5 HYPERPIGMENTATION & DARK SPOT TREATMENT 252
9.4.8.5.1 DARK SPOT CORRECTORS 252
9.4.8.5.1.1 DNA-BASED SPOT FADING TREATMENTS 252
9.4.8.5.1.2 RNA-POWERED DISCOLORATION REDUCERS 252
9.4.8.5.2 UNEVEN SKIN TONE CORRECTION 253
9.4.8.5.2.1 DNA-BASED SKIN BRIGHTENING MASKS 253
9.4.8.5.2.2 GENE-TARGETED EVEN SKIN TONE SOLUTIONS 253
9.4.8.5.3 MELANIN-INHIBITING SERUMS 253
9.4.8.5.3.1 DNA-BASED TYROSINASE INHIBITORS 253
9.4.8.5.3.2 RNA-POWERED BRIGHTENING SERUMS 253
9.4.8.5.4 POST-INFLAMMATORY HYPERPIGMENTATION (PIH) TREATMENTS 254
9.4.8.5.4.1 NUCLEIC ACID-INFUSED ACNE MARK CORRECTORS 254
9.4.8.5.4.2 RNA-BASED REDNESS-REDUCING CREAMS 254
9.4.8.6 ANTI-AGING & WRINKLE REDUCTION 255
9.4.8.6.1 COLLAGEN-BOOSTING FORMULATIONS 255
9.4.8.6.1.1 DNA-INFUSED COLLAGEN SERUMS 255
9.4.8.6.1.2 RNA-BASED PEPTIDE BOOSTERS 255
9.4.8.6.1.3 GENE-STIMULATING COLLAGEN MASKS 255
9.4.8.6.1.4 OTHERS 255
9.4.8.6.2 SKIN FIRMING & ELASTICITY IMPROVEMENT 256
9.4.8.6.2.1 DNA-BASED SKIN TIGHTENING SERUMS 256
9.4.8.6.2.2 RNA-POWERED ELASTICITY-ENHANCING CREAMS 256
9.4.8.6.2.3 NUCLEIC ACID-INFUSED FACIAL LIFTING MASKS 256
9.4.8.6.2.4 OTHERS 256
9.4.8.6.3 FINE LINE TREATMENT 257
9.4.8.6.3.1 FOREHEAD LINE CORRECTORS 257
9.4.8.6.3.2 CROW’S FEET REDUCTION CREAMS 257
9.4.8.6.3.3 UNDER-EYE WRINKLE SERUMS 257
9.4.8.6.3.4 NASOLABIAL FOLD TREATMENT 257
9.4.8.6.3.5 OTHERS 257
9.4.8.6.4 DEEP WRINKLE REPAIR 258
9.4.8.6.4.1 DNA-BASED RETINOL ALTERNATIVES 258
9.4.8.6.4.2 EPIGENETIC WRINKLE-REDUCING SERUMS 258
9.4.8.6.4.3 OTHERS 258
9.4.8.7 SENSITIVE SKIN CARE & INFLAMMATION REDUCTION 259
9.4.8.7.1 SOOTHING & ANTI-REDNESS FORMULATIONS 259
9.4.8.7.1.1 RNA-BASED ROSACEA TREATMENTS 259
9.4.8.7.1.2 DNA-INFUSED CALMING MASKS 259
9.4.8.7.2 HYPOALLERGENIC DNA-BASED SKINCARE 260
9.4.8.7.2.1 SENSITIVE SKIN RNA CREAMS 260
9.4.8.7.2.2 FRAGRANCE-FREE DNA SERUMS 260
9.4.8.7.3 ANTI-INFLAMMATORY NUCLEIC ACID TREATMENTS 260
9.4.8.7.3.1 DNA-POWERED CYTOKINE-REDUCING SERUMS 260
9.4.8.7.3.2 RNA-BASED IRRITATION-REDUCING GELS 260
9.5 NUCLEIC ACID SPORTS FOOD ADDITIVES 261
9.5.1 SPORTS SUPPLEMENTS 262
9.5.1.1 POWDER 262
9.5.1.2 CAPSULES 262
9.5.1.3 OTHERS 262
9.5.2 SPORTS FOOD 262
10 EUROPE NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY SOURCE 263
10.1 OVERVIEW 264
10.2 NATURAL NUCLEIC ACIDS 265
10.2.1 PLANT-BASED 266
10.2.2 MARINE-DERIVED 266
10.2.3 OTHERS 266
10.3 SYNTHETIC NUCLEIC ACIDS 266
11 EUROPE NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY END USER 267
11.1 OVERVIEW 268
11.2 INDIVIDUAL CONSUMERS/ HOME HEALTHCARE 269
11.2.1 WOMEN 270
11.2.2 MEN 270
11.2.3 UNISEX 270
11.3 PROFESSIONAL/FACILITY USE 270
11.3.1 DERMATOLOGY CLINICS 271
11.3.2 BEAUTY SALONS & SPAS 271
11.3.3 SPECIALTY CLINICS 271
11.3.4 HOSPITAL 271
11.3.5 OTHERS 271
12 EUROPE NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY DISTRIBUTION CHANNEL 272
12.1 OVERVIEW 273
12.2 DIRECT TENDER 274
12.3 RETAIL SALES 275
12.3.1 BY TYPE 275
12.3.1.1 STORE BASED 276
12.3.1.1.1 SUPERMARKETS/HYPERMARKETS 276
12.3.1.1.2 SPECIALTY BEAUTY STORES 276
12.3.1.1.3 PHARMACIES & DRUGSTORES 276
12.3.1.1.4 DERMATOLOGY CLINICS & MEDICAL SPAS 276
12.3.1.1.5 TRAVEL RETAIL 276
12.3.1.1.6 OTHERS 276
12.3.1.2 NON STORE BASED 277
12.3.1.2.1 E-COMMERCE/PHARMACY WEBSITES 277
12.3.1.2.2 COMPANY-OWNED WEBSITES 277
12.4 OTHERS 277
13 EUROPE NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY REGION 278
13.1 EUROPE 279
13.1.1 GERMANY 301
13.1.2 FRANCE 321
13.1.3 U.K. 341
13.1.4 ITALY 361
13.1.5 RUSSIA 381
13.1.6 SPAIN 401
13.1.7 BELGIUM 421
13.1.8 NETHERLANDS 441
13.1.9 DENMARK 461
13.1.10 SWITZERLAND 481
13.1.11 NORWAY 501
13.1.12 SWEDEN 521
13.1.13 FINLAND 541
13.1.14 TURKEY 561
13.1.15 POLAND 581
13.1.16 REST OF EUROPE 601
14 EUROPE NUCLEIC ACID THERAPEUTICS MARKET, COMPANY LANDSCAPE 602
14.1 COMPANY SHARE ANALYSIS: EUROPE 602
15 COMPANY PROFILES 603
15.1 PFIZER INC. 603
15.1.1 COMPANY SNAPSHOT 603
15.1.2 REVENUE ANALYSIS 603
15.1.3 COMPANY SHARE ANALYSIS 604
15.1.4 PRODUCT PORTFOLIO 604
15.1.5 RECENT DEVELOPMENTS 604
15.2 BIOGEN 605
15.2.1 COMPANY SNAPSHOT 605
15.2.2 RECENT FINANCIALS 605
15.2.3 COMPANY SHARE ANALYSIS 606
15.2.4 PRODUCT PORTFOLIO 606
15.2.5 RECENT DEVELOPMENTS/NEWS 606
15.3 ALNYLAM PHARMACEUTICALS, INC. 607
15.3.1 COMPANY SNAPSHOT 607
15.3.2 RECENT FINANCIALS 607
15.3.3 COMPANY SHARE ANALYSIS 608
15.3.4 PRODUCT PORTFOLIO 608
15.3.5 RECENT NEWS 609
15.4 SAREPTA THERAPEUTICS, INC. 610
15.4.1 COMPANY SNAPSHOT 610
15.4.2 REVENUE ANALYSIS 610
15.4.3 COMPANY SHARE ANALYSIS 611
15.4.4 PRODUCT PORTFOLIO 611
15.4.5 RECENT DEVELOPMENT 611
15.5 IONIS PHARMACEUTICALS, INC. 612
15.5.1 COMPANY SNAPSHOT 612
15.5.2 REVENUE ANALYSIS 612
15.5.3 COMPANY SHARE ANALYSIS 613
15.5.4 PIPELINE PRODUCT PORTFOLIO 613
15.5.5 RECENT DEVELOPMENTS 614
15.6 ASTRAZENECA 615
15.6.1 COMPANY SNAPSHOT 615
15.6.2 RECENT FINANCIALS 616
15.6.3 PIPELINE PRODUCT PORTFOLIO 616
15.6.4 RECENT DEVELOPMENT 618
15.7 MODERNA, INC. 619
15.7.1 COMPANY SNAPSHOT 619
15.7.2 RECENT FINANCIALS 619
15.7.3 PIPELINE PRODUCT PORTFOLIO 620
15.7.4 RECENT DEVELOPMENT 620
15.8 NOVARTIS AG 621
15.8.1 COMPANY SNAPSHOT 621
15.8.2 REVENUE ANALYSIS 622
15.8.3 PRODUCT PORTFOLIO 622
15.8.4 RECENT DEVELOPMENTS 623
15.9 SPARK THERAPEUTICS, INC. 624
15.9.1 COMPANY SNAPSHOT 624
15.9.2 PIPELINE PRODUCT PORTFOLIO 624
15.9.3 RECENT DEVELOPMENT 624
15.10 ZHEJIANG HAICHANG BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. 625
15.10.1 COMPANY SNAPSHOT 625
15.10.2 PIPELINE PRODUCT PORTFOLIO 625
15.10.3 RECENT DEVELOPMENT 626
16 EUROPE NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET: COMPANY LANDSCAPE 627
16.1 COMPANY SHARE ANALYSIS: EUROPE 627
17 COMPANY PROFILES 628
17.1 REMY LAURE 628
17.1.1 COMPANY SNAPSHOT 628
17.1.2 COMPANY SHARE ANALYSIS 628
17.1.3 PRODUCT PORTFOLIO 629
17.1.4 RECENT DEVELOPMENT 629
17.2 NEOVA 630
17.2.1 COMPANY SNAPSHOT 630
17.2.2 COMPANY SHARE ANALYSIS 630
17.2.3 PRODUCT PORTFOLIO 631
17.2.4 RECENT DEVELOPMENT 634
17.3 MOONGLOW 635
17.3.1 COMPANY SNAPSHOT 635
17.3.2 COMPANY SHARE ANALYSIS 635
17.3.3 PRODUCT PORTFOLIO 636
17.3.4 RECENT DEVELOPMENT 639
17.4 THE NAKED CHEMIST 640
17.4.1 COMPANY SNAPSHOT 640
17.4.2 COMPANY SHARE ANALYSIS 640
17.4.3 PRODUCT PORTFOLIO 641
17.4.4 RECENT DEVELOPMENT 641
17.5 SKINSHIFT 642
17.5.1 COMPANY SNAPSHOT 642
17.5.2 COMPANY SHARE ANALYSIS 642
17.5.3 PRODUCT PORTFOLIO 643
17.5.4 RECENT DEVELOPMENT 644
17.6 BIO JOUVANCE PARIS CONSUMER 645
17.6.1 COMPANY SNAPSHOT 645
17.6.2 PRODUCT PORTFOLIO 645
17.6.3 RECENT DEVELOPMENT 645
17.7 DNA SKIN INSTITUTE 646
17.7.1 COMPANY SNAPSHOT 646
17.7.2 PRODUCT PORTFOLIO 646
17.7.3 RECENT DEVELOPMENT 647
17.8 JULIETTE ARMAND 648
17.8.1 COMPANY SNAPSHOT 648
17.8.2 PRODUCT PORTFOLIO 648
17.8.3 RECENT DEVELOPMENT 648
17.9 KALICHEM S.R.L. 649
17.9.1 COMPANY SNAPSHOT 649
17.9.2 PRODUCT PORTFOLIO 649
17.9.3 RECENT DEVELOPMENT 649
17.10 NIPPON PAPER INDUSTRIES CO., LTD. 650
17.10.1 COMPANY SNAPSHOT 650
17.10.2 REVENUE ANALYSIS 650
17.10.3 PRODUCT PORTFOLIO 651
17.10.4 RECENT DEVELOPMENT 651
17.11 POSTQUAM 652
17.11.1 COMPANY SNAPSHOT 652
17.11.2 PRODUCT PORTFOLIO 652
17.11.3 RECENT DEVELOPMENT 655
17.12 SHOPATDNA.COM 656
17.12.1 COMPANY SNAPSHOT 656
17.12.2 PRODUCT PORTFOLIO 656
17.12.3 RECENT DEVELOPMENT 657
18 QUESTIONNAIRE 658
19 RELATED REPORTS 661